Side-by-side · Research reference

LivagenvsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/32 cited

BPhase 2HUMAN-REVIEWED8/46 cited

Livagen

Khavinson Bioregulator · Hepatoprotective Tetrapeptide

50%Dipeptidase inhibitionTimofeeva 2005

Oral / SQRoutes tested

LiverTarget tissueKhavinson 2001

Oral or SQ · Tissue-specific to liver

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

Livagen

TB-500

Primary target

Hepatocyte protein synthesis machineryBrodskiĭ 2001

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001 Khavinson 2001

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

—

Endogenous protein at baseline; supplementation amplifies

Origin

Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

Livagen

TB-500

Animal dose (oral)

Not specified in abstracts; 2-week administration protocolTimofeeva 2005

Per os administration in rats.

—

Duration (experimental)

2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005 Brodskiĭ 2001

—

Route

Oral or subcutaneous

Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005

—

Evidence basis

Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005 Brodskiĭ 2001 Khavinson 2002

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Human data

None in provided literature

—

Standard dose

—

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Frequency

—

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

—

1 mg per injection

Duration

—

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

—

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

—

Evening or pre-rest preferred (anecdotal)

Half-life

—

~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter

Livagen

TB-500

Reported adverse effects

None documented in animal studies

—

Human safety data

No human trials in provided literature

—

Peptide hydrolysis

Weakly hydrolyzed; minimal breakdown by intestinal enzymesTimofeeva 2005

—

Injection site reaction

—

Mild erythema, transient pain

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid

Long-term safety

—

Unknown beyond Phase 2

Absolute Contraindications

Livagen

—

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

Livagen

—

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

Livagen

TB-500

1. Route selection

Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005 Khavinson 2001

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Timing

No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Age-dependent response

Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005

Evening or pre-sleep is most common anecdotal timing.

4. Storage

—

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Needle

—

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Livagen

— no documented stacks

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair